Abstract: The present disclosure provides a lipid nanoparticle to treat, prevent or diagnose a central nervous system disease, disorder, trauma or injury, the lipid nanoparticle comprising: a non-cationic helper lipid; a sterol; a hydrophilic polymer-lipid conjugate; an ionizable, amino amino lipid having a pKa between 5.0 and 7.0; and an mRNA having a nucleic acid sequence encoding for a secretory polypeptide for treating, preventing or diagnosing the central nervous system disease, disorder, trauma or injury, the secretory polypeptide being capable of secretion from a cell of the central nervous system into a interstitial and/or cerebrospinal fluid of a subject. Further provided are methods for administration of the lipid nanoparticles to treat, prevent or diagnose the central nervous system disease, disorder, trauma or injury and uses of such lipid nanoparticles.

Abstract: Provided are methods for treating or preventing brain edema in a subject by administering an inhibitor of SLC26A11 to the subject. Also included are methods for preventing cell death, cell swelling, or elevated internal concentration of chloride ions in a cell by contacting the cell with an inhibitor of SLC26A11.

Abstract: Provided are methods for treating or preventing brain edema in a subject by administering an inhibitor of SLC26A11 to the subject. Also included are methods for preventing cell death, cell swelling, or elevated internal concentration of chloride ions in a cell by contacting the cell with an inhibitor of SLC26A11.

Abstract: A method of determining whether an individual has schizophrenia or the propensity to develop schizophrenia is provided. The method involves the detection of autoantibodies to the angiotensin AT1 receptor. Diagnostic kits and assays arc also provided within the scope of the invention.